Adicet bio receives fda fast track designation for adi-001 in lupus nephritis

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the u.s. food and drug administration (fda) has granted fast track designation to adi-001 for the potential treatment of relapsed/refractory class iii or class iv lupus nephritis. “the fda's decision to grant adi-001 fast track designation for lupus nephritis.
ACET Ratings Summary
ACET Quant Ranking